Issues with your “analysis”, 50% sales penetration is rather easy to achieve when there are no other approved or working treatment alternatives. If approved the MSB treatment would become SOC for SRaGVHD in children. Since we can assume that the vast majority of the patients who have received a bone marrow transplant are insured they will be able to access this treatment.
In addition the P/E ratio for pharmacy in the US is a little over 22 having been averaging 44 over the last 3 years. This multiple is likely to be a big underestimate for a company this early in its production history and with a number of much larger markets at advanced stages of investigation.
Issues with your “analysis”, 50% sales penetration is rather...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 54704 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.020 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |